资讯

The American Journal of Managed Care8 天
FDA Approves First Treatment for KRAS-Mutated Recurrent LGSOC
The combination of avutometinib and defactinib is the first FDA-approved treatment for KRAS-mutated recurrent LGSOC. Approval was based on the phase 2 RAMP-201 trial, showing a 44% overall ...
Medscape18 天
FDA Approves First One-Time Topical Treatment for Recessive Dystrophic Epidermolysis ...
Today, the US Food and Drug Administration (FDA) approved prademagene ... said in its press release announcing approval. The list price for the one-time treatment will be $3.1 million, according ...
WebMD15 天
FDA Approves New Long-Term Treatment for Myasthenia Gravis
May 2, 2025 -- The FDA has approved a new treatment for generalized myasthenia gravis (gMG), a disease that causes severe muscle weakness, faster muscle fatigue, and difficulty in speaking and ...
Yahoo Finance17 天
FDA Approves Johnson & Johnson’s IMAAVYTM (nipocalimab-aahu) a New Treatment for ...
New York, April 30, 2025 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) applauds the U.S. Food and Drug Administration (FDA) approval of IMAAVY TM (nipocalimab-aahu) for the treatment of ...
Longview News-Journal11 天
FDA Approves New, Low-Dose Chlorthalidone for the Treatment of Hypertension in Adults ...
May 6, 2025 /PRNewswire/ -- PRM Pharma, LLC today announced the U.S. Food and Drug Administration (FDA) approval of HemiClor (12.5 mg chlorthalidone) tablets for the treatment of hypertension in ...